STAMFORD, Conn. - Cara Therapeutics, Inc. (NASDAQ: NASDAQ:CARA), a commercial-stage biopharmaceutical company, has scheduled a conference call and live audio webcast for March 4, 2024, at 4:30 p.m. EST to discuss its fourth quarter and full year financial results for 2023, along with a corporate update.
The company, known for its focus on pruritus treatments, invites interested parties to register for the conference call where they will receive dial-in numbers and a unique PIN to access the event. Additionally, the call will be accessible as a live audio webcast and an archived replay on the company's website, under the Investors section.
Cara Therapeutics has made a significant contribution to the field of pruritus treatment with its FDA-approved KORSUVA® injection, which is currently the only treatment endorsed by the FDA for moderate-to-severe pruritus in adults undergoing hemodialysis due to chronic kidney disease. Building on this, the company is also progressing with the development of an oral formulation of difelikefalin. This formulation is being evaluated through a Phase 2/3 clinical program for patients with notalgia paresthetica, a condition characterized by chronic itching of the upper back and for which there are no FDA-approved therapies.
The forthcoming financial results and corporate update are anticipated to shed light on the company's performance and strategic direction, including the advancement of its product pipeline. As a leader in its field, Cara Therapeutics continues to focus on new treatment paradigms aiming to improve patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.